Top Page
Acrux
(Sydney:ACR)
Acrux (ACR) vs. iShares MSCI Australia ETF (EWA)
Acrux Business Overview & Revenue Model
Acrux Financial Statement Overview
| Breakdown | |||||
| TTM | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 | Jun 2020 |
|---|---|---|---|---|---|
| Income Statement | Total Revenue | ||||
| 802.00K | 5.09M | 8.43M | 1.72M | 1.34M | 1.25M | Gross Profit |
| -1.82M | 1.13M | 1.95M | -4.65M | -7.59M | -3.76M | EBIT |
| -10.68M | -8.57M | -3.39M | -12.97M | -16.25M | -12.08M | EBITDA |
| -8.98M | -8.06M | -2.79M | -12.29M | -15.59M | -11.37M | Net Income Common Stockholders |
| -5.99M | -5.80M | -764.00K | -9.83M | -12.63M | -9.47M |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | ||||
| 3.33M | 2.94M | 6.23M | 5.83M | 15.27M | 9.21M | Total Assets |
| 7.79M | 8.96M | 14.30M | 15.27M | 24.20M | 18.52M | Total Debt |
| 2.11M | 3.70M | 2.35M | 2.08M | 2.23M | 2.40M | Net Debt |
| -1.21M | 759.00K | -3.88M | -3.75M | -13.04M | -6.80M | Total Liabilities |
| 4.38M | 5.69M | 5.60M | 6.18M | 5.73M | 5.67M | Stockholders Equity |
| 3.41M | 3.28M | 8.70M | 9.09M | 18.47M | 12.85M |
| Cash Flow | Free Cash Flow | ||||
| -4.41M | -4.58M | 584.00K | -9.28M | -11.52M | -8.79M | Operating Cash Flow |
| -4.27M | -4.30M | 703.00K | -8.82M | -11.41M | -8.53M | Investing Cash Flow |
| -143.00K | -276.00K | -119.00K | -465.00K | -102.00K | -254.00K | Financing Cash Flow |
| 3.17M | 1.29M | -183.00K | -155.00K | 17.58M | -159.00K |
Acrux Technical Analysis
Acrux Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
57 Neutral | AU$6.39M | 58.00 | 2.14% | ― | ― | ― | |
54 Neutral | AU$8.97M | 9.63 | 26.99% | ― | ― | 51.85% | |
53 Neutral | $5.24B | 3.32 | -44.36% | 6.63% | 16.78% | -0.12% | |
42 Neutral | AU$8.06M | ― | -180.09% | ― | ― | 28.57% | |
38 Underperform | $7.75M | ― | -132.58% | ― | -92.98% | -741.67% | |
| $6.57M | ― | -43.32% | ― | ― | ― | ||
37 Underperform | AU$7.93M | ― | -80.47% | ― | -41.19% | 20.93% |
Acrux Corporate Events
Acrux Ltd has announced the appointment of John Warmbrunn as a director effective from June 1, 2025. The Initial Director’s Interest Notice reveals that Mr. Warmbrunn currently holds no securities or relevant interests in the company, indicating a fresh start in his new role without prior financial ties to Acrux.
Acrux Ltd has announced a change in the interest of its director, Don Brumley, who has increased his holdings by acquiring 448,334 ordinary shares through the exercise of vested unlisted rights issued in 2024. This change reflects a strategic move by the director to increase his stake in the company, potentially signaling confidence in Acrux’s future performance and aligning his interests more closely with those of the shareholders.
Acrux Limited has announced the quotation of 448,334 ordinary fully paid securities on the Australian Securities Exchange (ASX) as of May 23, 2025. This move follows the cessation of transfer restrictions on securities previously issued under an employee incentive scheme. The announcement indicates a strategic step in Acrux’s financial operations, potentially enhancing its market liquidity and providing more investment opportunities for stakeholders.
Acrux, in partnership with TruPharma, has launched Dapsone 7.5% Gel in the United States, a topical prescription medicine for treating acne vulgaris in children aged 9 and older. This product is uniquely marketed in a tube presentation, differentiating it from competitors’ pump bottle packaging, and is manufactured in the U.S. The launch underscores Acrux’s strategic capability to develop and commercialize its pharmaceutical pipeline, with the U.S. market for similar products generating over $43 million in sales annually.
Acrux Limited has announced the appointment of John Warmbrunn as the new CEO and Managing Director, effective June 1, 2025, following the retirement of Michael Kotsanis. Warmbrunn brings over 25 years of experience in the healthcare sector, with a strong track record in international business growth and leadership roles at companies like Ego Pharmaceuticals and Bendigo Community Telco. His appointment is expected to drive Acrux’s next phase of growth, particularly in expanding its international market presence.
Acrux Limited has reported significant growth in product-based revenue following the successful launch of new products in late 2024 and early 2025. The company raised $3.989 million through a placement and share purchase plan, and secured $1.729 million in short-term funding from Radium Capital. These financial activities, coupled with the positive market reception of their products, position Acrux to achieve its strategic goal of sustaining future product development.
Acrux Limited announced a change in the address of its registry office in Sydney, effective from April 14, 2025. The registry, managed by MUFG Corporate Markets (AU) Limited, will relocate to Liberty Place, Level 41, 161 Castlereagh St, Sydney. This change is part of the company’s ongoing operational adjustments and does not affect contact details, ensuring continuity for stakeholders.
Acrux Limited announced a change in the director’s interest, with Ross Dobinson acquiring 571,428 free attaching options. This change reflects the issue of options approved at an Extraordinary General Meeting in February 2025, aligning with the terms for Placement and SPP participants. The announcement indicates a strategic move to incentivize leadership and align interests with stakeholders, potentially impacting the company’s operational dynamics and stakeholder relations.
Acrux Limited has announced the quotation of 8,829,411 options on the Australian Securities Exchange (ASX), set to expire on February 19, 2027. This move is part of previously announced transactions and could enhance the company’s financial flexibility and market presence, potentially impacting stakeholders by increasing investment opportunities.
Acrux Limited has received a $1.73 million advance from Radium Capital related to its FY25 R&D Tax Incentive. This funding provides early access to the expected rebate, supporting product development and working capital management, and is secured against the anticipated rebate from the Australian Taxation Office.